FBS Gamma Irradiated — 25–45 kGy | GMP Manufacturing & Maximum Viral Safety | SeamlessBio
FBS Gamma Irradiated — 25–45 kGy | GMP Manufacturing & Maximum Viral Safety
Gamma irradiation at 25–45 kGy provides the broadest pathogen reduction available for FBS, inactivating bacteria, mycoplasma, viruses, and prions beyond what is achieved by sterile filtration alone. Gamma irradiated FBS is the specification of choice for GMP manufacturing environments, ATMP ancillary material use, and any application where viral safety documentation must meet the highest regulatory standard.
Gamma irradiation vs. heat inactivation: These are different processes with different purposes. Heat inactivation (56°C/30 min) destroys complement only. Gamma irradiation (25–45 kGy) provides broad pathogen reduction — bacteria, viruses, mycoplasma, and prions — without affecting complement. Both can be combined. For GMP manufacturing, gamma irradiation is the standard viral safety treatment for serum.
What Gamma Irradiation Achieves
| Target | Reduction at 25–45 kGy | Mechanism |
|---|
| Non-enveloped viruses (parvovirus B19, reovirus) | ≥4 log10 reduction validated | DNA/RNA strand breaks prevent replication |
| Enveloped viruses (HIV, BVD, herpesvirus) | ≥4–6 log10 reduction | Membrane disruption + nucleic acid damage |
| Mycoplasma | Complete inactivation | DNA damage prevents replication |
| Bacteria (spore-forming and vegetative) | Complete inactivation at 25 kGy | DNA double-strand breaks |
| Prions (TSE/BSE agents) | Partial reduction — not complete | Protein unfolding — incomplete at these doses |
| Growth factors (EGF, FGF, PDGF) | Largely preserved at 25 kGy | Proteins more radiation-resistant than nucleic acids |
| Complement activity | Partially preserved (unlike HI) | Complement proteins survive at standard doses |
Regulatory Context
| Guideline | Relevance to Gamma Irradiated FBS |
|---|
| EMA/410/01 (ATMP guideline) | Gamma irradiation recommended for bovine serum used in cell therapy manufacturing to reduce adventitious agent risk |
| Ph. Eur. 5.2.12 (Ancillary materials for ATMP) | Viral safety documentation requirements — gamma irradiation CoA supports compliance |
| Eudralex Vol. 4 Part IV (GMP for ATMPs) | Ancillary material viral safety — gamma irradiated FBS with validated irradiation certificate preferred |
| USP <1043> Ancillary materials | Viral reduction documentation for biological ancillary materials in cell therapy |
Specifications
| Parameter | Specification |
|---|
| Irradiation dose | 25–45 kGy — validated per ISO 11137 |
| Irradiation validation | Certificate of irradiation with dose mapping data included |
| Sterile filtration | 0.1 µm pre-irradiation |
| Endotoxin | Tested per lot (LAL) |
| Mycoplasma | Tested — negative (pre-irradiation) |
| Origin | EU and/or US — CoO included |
| GMP documentation | CoA, CoO, irradiation certificate, TSE/BSE statement — available |
| ATMP documentation | Ph. Eur. 5.2.12 declaration, Eudralex Vol. 4 Part IV — on request |
| Volumes | 100 mL, 500 mL | Bulk on request |
| Storage | −20°C |
FBS Portfolio — All Grades
Request FBS Gamma Irradiated
Request GMP documentation package
Contact: info@seamlessbio.de | +49 851 37932226
